Aldevron, a global leader in the manufacture of plasmid DNA, mRNA and proteins, has promoted Venkata Indurthi to Vice President of Research and Development (R&D). He will begin this new role immediately and continue reporting to John Ballantyne, Co-founder and Chief Scientific Officer while having direct access to Aldevron’s senior executive team.
As clustered regularly interspaced short palindromic repeats (CRISPR) therapies progress to the clinic, the key CRISPR editing components are primarily being delivered by recombinant virus, RNA, or as ribonucleoprotein (RNP), which is the active complex formed by the guide RNA and Cas9 protein. RNPs have several attractive properties as a delivery format, particularly in the manufacturing of ex vivo cellular therapies, the most rapidly growing segment of the CRISPR therapeutics market.
As a Project Scientist for the University of California, Los Angeles, Dr. Mark DeWitt has developed a phase 1 GMP-compatible protocol for correcting diseases that cause gene mutations using a CRISPR-Cas9 modular, non-viral gene editing platform. His specific research focuses on a treatment for sickle cell anemia that is more accessible and less costly than a bone marrow transplant—currently, the only way to address the disease.
Over the past year, DeWitt has partnered with Aldevron and Synthego, industry leaders in CRISPR-Cas9 nucleases and gRNA manufacturing, respectively.
Aldevron, a leading manufacturer of plasmid DNA, proteins and mRNA, today announced the sale of its Germany based antibody discovery business. Brian Walters, current president of the business unit and longtime employee of Aldevron, led a group of investors to purchase the business for an undisclosed amount. The transaction is effective immediately.
Aldevron The First To Rapidly Discover Human Antibodies Using Ligands Omnirat® Platform And Berkeley Lights Beacon® Instrument
Aldevron, a leading provider of antibody discovery and production services, today announced the successful discovery of human antibodies utilizing the combination of three powerful platforms, Aldevron’s GENOVAC® genetic immunization and cell-based screening, Ligand’s OmniRat® therapeutic antibody platform and Berkeley Lights’ Beacon® platform.
Aldevron LLC, a company angling for a role in the production of Covid-19 vaccines, hired Rachel Lei as its first general counsel and corporate secretary.
Lei became Aldevron’s first general counsel in June. She joins new chief executive officer Kevin Ballinger, hired the following month, among other recent additions to the North Dakota-based company’s leadership team.
Rachel Lei has joined Aldevron as its new General Counsel and Corporate Secretary. Lei will advise the Board of Directors and CEO on issues of overarching importance to Aldevron and will assist in setting and implementing Aldevron’s overall strategic direction , building and overseeing Aldevron’s legal department to ensure that its legal function operates as a true business partner.
In the news: GEN Magazine - Plasmid Manufacturer Scales Up Production Capacity to Serve New Therapeutics
A plasmid DNA manufacturer is planning to scale up its production capacity to meet the growing needs of gene therapy. Aldevron, a company based in North Dakota, expects to open a new 189,000 sq. ft facility in spring 2021 to add to their existing 70,000 sq. ft of manufacturing space.